Cagrilintide

Amylin / Obesity

Appetite suppression and weight loss

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide
Primary mechanism: Amylin receptor agonism
Primary market use: Obesity

Pharmacology

Molecular weight (Da): ~4100
Oral bioavailability: N/A
Half-life: ~6-8 d
Route tags: SubQ; Injectable; route-dependent
Evidence level: Clinical
Clinical status: Investigational
Value-for-money score: 6 / 10

Reported protocol signal

No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Weight regain likely if stopped without maintained lifestyle changes

Sources

https://clinicaltrials.gov/